British Journal of Medical & Surgical Urology
Volume 2, Issue 5 , Pages 191-196 , September 2009

A large proportion of patients with prostate cancer undergoing androgen deprivation therapy continue to die from non-cancer causes in the PSA era

  • Vivek K. Wadhwa
    • ,
  • Robin Weston
    • ,
  • Nigel J. Parr

      Affiliations

    • Corresponding Author InformationCorresponding author at: Department of Urology, Ward 14, Wirral University Teaching Hospitals, Arrowe Park, Upton, Wirral, Merseyside, CH49 5PE, UK. Tel.: +44 151 678 5111x2233; fax: +44 151 604 7481.

Received 18 September 2008 ,Revised 9 June 2009 ,Accepted 15 June 2009.

References 

  1. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981–989
  2. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973;32:1126–1130
  3. The Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer: initial results of the medical council trial. Br J Urol. 1997;79:235–246
  4. Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993;85:979–987
  5. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  6. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297
  7. Kirk D. Timing and choice of androgen ablation. Prostate Cancer Prostatic Dis. 2004;7:217–222
  8. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomised trial SAKK 08/88. J Clin Oncol. 2004;22:4109–4118
  9. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868–1876
  10. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation therapy in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941–949
  11. Petersen RO. What should you ask your pathologist when contemplating minimally invasive therapy. In:  Dicker AP,  Merrick GS,  Waterman FM,  Valicenti RK,  Gomella LG editor. Basic and advanced techniques in prostate brachytherapy. 1st ed.. Taylor & Francis; 2005;p. 17–26[Chapter 3]
  12. Fouad MN, Mayo CP, Funkhouser EM, Hall HI, Urban DA, Kiefe CI. Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease. J Clin Epidemiol. 2004;57:721–729

PII: S1875-9742(09)00097-4

doi: 10.1016/j.bjmsu.2009.06.004

British Journal of Medical & Surgical Urology
Volume 2, Issue 5 , Pages 191-196 , September 2009

Article Tools

* Image Usage & Resolution